5.82
-0.06(-1.02%)
Currency In USD
| Previous Close | 5.88 |
| Open | 6.1 |
| Day High | 6.1 |
| Day Low | 5.76 |
| 52-Week High | 9.3 |
| 52-Week Low | 4.92 |
| Volume | 3,942 |
| Average Volume | 71,446 |
| Market Cap | 3.18M |
| PE | -0.32 |
| EPS | -17.94 |
| Moving Average 50 Days | 6.14 |
| Moving Average 200 Days | 6.52 |
| Change | -0.06 |
If you invested $1000 in Artelo Biosciences, Inc. (ARTL) since IPO date, it would be worth $13.91 as of June 25, 2025 at a share price of $5.82. Whereas If you bought $1000 worth of Artelo Biosciences, Inc. (ARTL) shares 5 years ago, it would be worth $48.26 as of June 25, 2025 at a share price of $5.82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Artelo Biosciences Announces Reverse Stock Split
GlobeNewswire Inc.
Jun 11, 2025 12:30 PM GMT
Shares Expected to Begin Trading on a Split-Adjusted Basis on June 13, 2025SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalin
Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
GlobeNewswire Inc.
Jun 05, 2025 1:00 PM GMT
SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derma
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression
GlobeNewswire Inc.
Jun 02, 2025 1:00 PM GMT
SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derma